The 44th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID 2026)

An antimicrobial stewardship intervention to reduce the use of piperacillin–tazobactam in children with acute appendicitis has been shown to result in improved clinical outcomes.

The V114-032 trial, presented at ESPID 2026, shows that administering the 15-valent pneumococcal conjugate vaccine (PCV15) reduces the incidence of first vaccine-type acute otitis media (VT-AOM) among healthy children.

Real-life use of letermovir in paediatric recipients of haematopoietic stem cell transplant (HSCT) is generally safe and prevents the development of cytomegalovirus (CMV) disease, as shown in a study presented at ESPID 2026.

In the treatment of scabies infection in children up to 2 years of age, age-based ivermectin dosing yields high response rates and is well-tolerated, according to the open-label phase 2 ITCHY 2 study.

An observational study shows an association between adjunctive clindamycin and reduced odds of mortality in children with invasive Group A streptococcal (iGAS) infections.